Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB00715"

Predicate	Value (sorted: default)
rdfs:label	"Paroxetine"
rdf:type	drugbank:drugs
drugbank:description	"Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D<sub>2</sub> or histamine H<sub>1</sub> receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT<sub>1A</sub> and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation. "
drugbank:drugCategory	drugcategory:Antidepressive Agents drugcategory:Serotonin Uptake Inhibitors
drugbank:interactsWith	drug:Amphetamine drug:Phentermine drug:Tramadol drug:Eletriptan drug:Metoprolol drug:Dicoumarol drug:Venlafaxine drug:Atomoxetine drug:Zolmitriptan drug:Treprostinil drug:Phenylpropanolamine drug:Triprolidine drug:Oxycodone drug:Tolmetin drug:Dextromethorphan drug:Propranolol drug:Fenfluramine drug:Mazindol drug:Linezolid drug:Trazodone drug:Sumatriptan drug:Galantamine drug:Tamoxifen drug:Thioridazine drug:Warfarin drug:Tamsulosin drug:Trimipramine drug:Risperidone drug:Tranylcypromine drug:Phenelzine drug:Terbinafine drug:Benzphetamine drug:Almotriptan drug:Tipranavir drug:Mesoridazine drug:Diethylpropion drug:Naratriptan drug:Rizatriptan drug:Frovatriptan drug:Ketoprofen drug:Tolterodine drug:Selegiline drug:Pimozide drug:Sibutramine drug:Anisindione drug:Carvedilol drug:Moclobemide drug:Propafenone drug:Dexfenfluramine drug:Isocarboxazid drug:St. John's Wort drug:Rasagiline drug:Ginkgo biloba drug:Acenocoumarol drug:Dihydrocodeine drug:Dextroamphetamine drug:Methamphetamine drug:Phendimetrazine drug:Tiaprofenic acid drug:Zuclopenthixol drug:Tetrabenazine drug:Iloperidone drug:Asenapine drug:Desvenlafaxine drug:Zuclopenthixol acetate drug:Zuclopenthixol decanoate
owl:sameAs	drug:Amphetamine drug:Phentermine drug:Tramadol drug:Eletriptan drug:Metoprolol drug:Dicoumarol drug:Venlafaxine drug:Atomoxetine drug:Zolmitriptan drug:Treprostinil drug:Phenylpropanolamine drug:Triprolidine drug:Oxycodone drug:Tolmetin drug:Dextromethorphan drug:Propranolol drug:Fenfluramine drug:Mazindol drug:Linezolid drug:Trazodone drug:Sumatriptan drug:Galantamine drug:Tamoxifen drug:Thioridazine drug:Warfarin drug:Tamsulosin drug:Trimipramine drug:Risperidone drug:Tranylcypromine drug:Phenelzine drug:Terbinafine drug:Benzphetamine drug:Almotriptan drug:Tipranavir drug:Mesoridazine drug:Diethylpropion drug:Naratriptan drug:Rizatriptan drug:Frovatriptan drug:Ketoprofen drug:Tolterodine drug:Selegiline drug:Pimozide drug:Sibutramine drug:Anisindione drug:Carvedilol drug:Moclobemide drug:Propafenone drug:Dexfenfluramine drug:Isocarboxazid drug:St. John's Wort drug:Rasagiline drug:Ginkgo biloba drug:Acenocoumarol drug:Dihydrocodeine drug:Dextroamphetamine drug:Methamphetamine drug:Phendimetrazine drug:Tiaprofenic acid drug:Zuclopenthixol drug:Tetrabenazine drug:Iloperidone drug:Asenapine drug:Desvenlafaxine drug:Zuclopenthixol acetate drug:Zuclopenthixol decanoate drug:DBSALT000132 drug:DBSALT000133

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines2/drugbank_small.nt

The resource appears as object in 132 triples

Context graph